Compare Eli Lilly And Co (LLY) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Paycom Software Inc — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while Paycom Software Inc trades at $231.94 (market cap $10.36B). The key difference: Eli Lilly And Co is far larger — about 100.4× Paycom Software Inc's market cap, and Paycom Software Inc pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Paycom Software Inc for 84 Days on average.
| LLY | PAYC | |
|---|---|---|
Market Cap | $1.04T | $10.36B |
Volume | 3,064,878 | 666,294 |
Sector | Health | Technology |
52-Week High | $1.28K | $240.52 |
52-Week Low | $799.57 | $113.59 |
Typical Hold Time | 93 Days | 84 Days |
Enterprise Value | $1.09T | $11.15B |
Dividend Yield | 0.59% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Paycom Software (PAYC) trades at $232.22, up 3.86% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.78 versus $2.38 expected, driven by 10% revenue growth and margin expansion. The company raised full-year 2026 guidance, targeting 7-8% revenue growth and improved EBITDA margins. Cash flow remains robust, with 2025 operating cash flow at $678.9 million.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and market volatility. Analyst consensus is mixed with a $207.75 price target below the current price, suggesting cautious optimism. Institutional buying activity supports bullish sentiment, though valuation multiples like a P/E of 24.33 warrant monitoring for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
